টুইনভির

It is a fixed-dose combination tablet containing Ledipasvir and Sofosbuvir for oral administration. Ledipasvir is an HCV NS5A inhibitor and Sofosbuvir is a nucleotide analog inhibitor of HCV NS5B polymerase.

ব্যবহার

Ledipasvir and Sofosbuvir combination is used for the treatment of chronic hepatitis C (CHC) genotype 1, 4 & 6 infection in adults.

টুইনভির এর দাম কত? টুইনভির এর দাম

সুচিপত্র

• টুইনভির
• কাজ
• খাওয়ার নিয়ম
• পার্শ্বপ্রতিক্রিয়া
• সতর্কতা
• মিথস্ক্রিয়া
• গর্ভাবস্থাকালীন ব্যবহার
• তীব্র ওভারডোজ
• অন্যান্য ওষুধের সাথে প্রতিক্রিয়া
• বৈপরীত্য
• সংরক্ষণ

খাওয়ার নিয়ম / ব্যবহারের নিয়ম

টুইনভির খাওয়ার নিয়ম / ব্যবহারের নিয়ম

Recommended dosage: One tablet (90 mg of Ledipasvir and 400 mg of Sofosbuvir) taken orally once daily with or without food

Recommended treatment duration:

• Treatment-naive with or without cirrhosis: 12 weeks
• Treatment-experienced without cirrhosis: 12 weeks
• Treatment-experienced with cirrhosis: 24 weeks

A dose recommendation cannot be made for patients with severe renal impairment or end stage renal disease.

পার্শ্বপ্রতিক্রিয়া

The most common adverse reactions with treatment with Ledipasvir and Sofosbuvir combination for 8, 12, or 24 weeks are fatigue and headache.

সতর্কতা

Bradycardia with Amiodarone coadministration: Serious symptomatic bradycardia may occur in patients taking Amiodarone, particularly in patients also receiving beta blockers, or those with underlying cardiac comorbidities and/or advanced liver disease. Coadministration of Amiodarone with Ledipasvir and Sofosbuvir combination is not recommended. In patients without viable treatment options, cardiac monitoring is recommended.

Use with other drugs containing sofosbuvir, is not recommended

মিথস্ক্রিয়া

• Coadministration with amiodarone may result in serious symptomatic bradycardia. Use of Ledipasvir and Sofosbuvir combination with Amiodarone is not recommended
• P-gp inducers (e.g., Rifampin, St. John’s wort): May alter concentrations of Ledipasvir and Sofosbuvir. Use of Ledipasvir and Sofosbuvir combination with P-gp inducers is not recommended

গর্ভাবস্থাকালীন ব্যবহার

Pregnancy Category B. There are no adequate and well-controlled studies with Ledipasvir and Sofosbuvir in pregnant women. Because animal reproduction studies are not always predictive of human response, this should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Lactation: It is not known whether Ledipasvir and Sofosbuvir and its metabolites are present in human breast milk.

বৈপরীত্য

This combination is contraindicated in patients with Known hypersensitivity to Ledipasvir, Sofosbuvir or any other ingredient in the product.

অতিরিক্ত সতর্কতা

Pediatric Use: Safety and effectiveness of Ledipasvir and Sofosbuvir have not been established in pediatric patients.

Geriatric Use: No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients. No dosage adjustment of Ledipasvir and Sofosbuvir is warranted in geriatric patients.

তীব্র ওভারডোজ

No specific antidote is available for overdose

অন্যান্য ওষুধের সাথে প্রতিক্রিয়া

সংরক্ষণ

Keep out of the reach of children. Keep in a cool & dry place. Protect from light.